Skip to main content
. 2000 Mar;15(3):175–182. doi: 10.1046/j.1525-1497.2000.02639.x

Table 3.

Results of Monte Carlo Simulation

Cost (SD), $ Utility (SD) Marginal Cost-Utility Ratio,*$/QALY
Histamine2-receptor antagonist 1,195 (915) 11.56 (0.27)
Proton pump inhibitor 1,412 (760) 11.76 (0.26) 13,000
Upper gastrointestinal series 1,516 (1065) 11.58 (0.29) 190,000
Esophagogastroduodenoscopy 2,145 (642) 11.61 (0.25) 230,000
*

Dollars per additional quality-adjusted life year; all comparisons against the histamine 2-receptor antagonist alternative.